Skip to Content
Merck
  • Reduction of adipogenesis and lipid accumulation by Taraxacum officinale (Dandelion) extracts in 3T3L1 adipocytes: an in vitro study.

Reduction of adipogenesis and lipid accumulation by Taraxacum officinale (Dandelion) extracts in 3T3L1 adipocytes: an in vitro study.

Phytotherapy research : PTR (2013-08-21)
Marta González-Castejón, Belén García-Carrasco, Raquel Fernández-Dacosta, Alberto Dávalos, Arantxa Rodriguez-Casado
ABSTRACT

In this in vitro study, we have investigated the ability of Taraxacum officinale (dandelion) to inhibit adipocyte differentiation and lipogenesis in 3T3-L1 preadipocytes. HPLC analysis of the three plant extracts used in this study-leaf and root extracts and a commercial root powder-identified caffeic and chlorogenic acids as the main phenolic constituents. Oil Red O staining and triglyceride levels analysis showed decreased lipid and triglyceride accumulation, respectively. Cytotoxicity was assessed with the MTT assay showing non-toxic effect among the concentrations tested. DNA microarray analysis showed that the extracts regulated the expression of a number of genes and long non-coding RNAs that play a major role in the control of adipogenesis. Taken together, our results indicate that the dandelion extracts used in this study may play a significant role during adipogenesis and lipid metabolism, and thus, supporting their therapeutic interest as potential candidates for the treatment of obesity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Caffeic acid, ≥98.0% (HPLC)
Supelco
Caffeic acid, matrix substance for MALDI-MS, ≥99.0% (HPLC)
Sigma-Aldrich
Chlorogenic acid, ≥95% (titration)
Chlorogenic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
trans-Caffeic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Chlorogenic acid, primary reference standard